Multi-center, Open-label, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection

Trial Profile

Multi-center, Open-label, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs INO 8000 (Primary) ; INO 8000 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors GeneOne Life Science
  • Most Recent Events

    • 04 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 07 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Feb 2017.
    • 09 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top